Digestive series the capsule) Patients with reflux symptoms refractory System: Bravo™ wireless capsule system (Endoscopic Endoscopy Unit, to PPI therapy who had normal or removal of the 23 males, 17 females Insertion: transnasally Agostino Gemelli equivocal endoscopic findings capsule) Level: IV Mean age: 42.5 years Placement: 5 cm above the upper margin of University Epistaxis Exclusion: the LOS Hospital, Catholic Quality: Q1 Indications: Pharyngeal irritation Patients with oesophageal varices, University of Duration: 24 or 48 hours CX (no Reflux symptoms that were refractory previous GI surgery, known coagulopathy Rome, Rome, comparator) to PPI therapy Comparator: NA or bleeding diathesis, cardiac Italy pacemakers, defibrillators or other P2 electromedical devices, significant comorbidity, pregnant women and patients <18 years of age No significant Nusrat, Roy & Retrospective 356 patients (65% females) Inclusion: Index test: adverse effects Bielefeldt () case series Mean age: 49.9 ± 0.8 years Not stated System: Bravo™ wireless capsule system during the study University of Indications: Exclusion: Insertion: not stated Pittsburgh Level: IV Evaluations of GORD, recurrent or Patients with pacemakers, implanted Placement: 6 cm above the endoscopically Medical Center, Quality: Q1 persistent symptoms after cardiac defibrillators, known oesophageal localised SCJ or 5 cm above the Pittsburgh, fundoplication, chest pain, varices, bleeding disorders or ongoing manometrically determined upper border of Pennsylvania, CX (no unexplained cough or other atypical anticoagulation the LOS USA comparator) symptoms Duration: 48 hours P2 Comparator: NA
Digestive Endoscopy Unit, Agostino Gemelli University Hospital, Catholic University of Rome, Rome, Italy series Level: IV Quality: Q1 CX (no comparator) P2 the capsule) 23 males, 17 females Mean age: 42.5 years Indications: Reflux symptoms that were refractory to PPI therapy Patients with reflux symptoms refractory to PPI therapy who had normal or equivocal endoscopic findings Exclusion: Patients with oesophageal varices, previous GI surgery, known coagulopathy or bleeding diathesis, cardiac pacemakers, defibrillators or other electromedical devices, significant comorbidity, pregnant women and patients <18 years of age System: Bravo™ wireless capsule system Insertion: transnasally Placement: 5 cm above the upper margin of the LOS Duration: 24 or 48 hours Comparator: NA (Endoscopic removal of the capsule) Epistaxis Pharyngeal irritation Nusrat, Roy & Bielefeldt () University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA Retrospective case series Level: IV Quality: Q1 CX (no comparator) P2 356 patients (65% females) Mean age: 49.9 ± 0.8 years Indications: Evaluations of GORD, recurrent or persistent symptoms after fundoplication, chest pain, unexplained cough or other atypical symptoms Inclusion: Not stated Exclusion: Patients with pacemakers, implanted cardiac defibrillators, known oesophageal varices, bleeding disorders or ongoing anticoagulation Index test: System: Bravo™ wireless capsule system Insertion: not stated Placement: 6 cm above the endoscopically localised SCJ or 5 cm above the manometrically determined upper border of the LOS Duration: 48 hours Comparator: NA No significant adverse effects during the study
1203-ContractedAssessmentReport-Catheter-free%20ambulatory%20pH%20test%20for%20GORD%20accessible.docx